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1. Introduction 
Studies employing genes sequence for genotyping analysis of microorganisms, are allowing 
the knowledge expansion about the microbiota of the human gastrointestinal tract (GIT). 
Only in the last decade, the number of species detected molecularly has exceeded on a large 
scale the number of species accessible by cultivation-dependent methods. 
The molecular techniques ranging from the identification of intestinal microbiota, 
particularly probiotic microorganism in different environments, detection of pathogenicity 
genes in foods, identification and quantification using real-time polimerase chain reaction 
(PCR), till studies with proteomics approach, which evaluate the expression of genes of 
interest or the changes in the host due to the microorganisms impact, have providing new 
perspectives in the investigation of diversity, abundance and dynamics of the intestinal 
ecosystem. 
Research on probiotics microorganisms has focused on methods of evaluating the GIT 
microbiota survival and function, cross-talk between the intestinal microbiota and the host 
and the probiotic interactions with the immune system. Actually, the data generated by 
clinical studies reinforces the effect of this microbiota on the human health.  
A substantial number of clinical studies have supported the idea that health can be affected 
by the daily consumption of probiotics. The exploitation of these data allows understanding 
the mechanisms by which probiotic microorganisms survive the passage through the GI 
tract to interact with the resident microbiota, and affect physiological functions in the host. 
Thus the probiotics have been extensively studied and commercially explored in many 
different products in the world. 
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2. The gastrointestinal microbiota  
The human gastrointestinal tract (GIT) is composed of several connected organs that are 
involved in nutrient conversion and providing energy sources from the food absorbed. This 
complex system has a well-known anatomical architecture that is approximately 7 m long, 
comprising a 300 m2 surface area in adults. From the mouth to the colon, there exists a complex 
microbiota consisting of facultative and strict anaerobes, including streptococci, bacteroides, 
lactobacilli and yeasts. The microbial community, inhabitants of these organs, is collectively 
called the gut microbiota and is composed of a myriad of microbial cells that outnumber the 
cells number of our body by a factor of at least 10. In addition, there is a great diversity of 
species, some of which have not yet been identified or cultured, and understanding the 
dynamics of this population is a challenge to the TGI ecologist (Zoetendal, et al., 2008).  
However, the development of molecular biology since the discovery of polymerase chain 
reaction (PCR) by Mullins and Fallona (1996) up to the current approaches "omics", have focused 
on molecular characterization of specific environments such as GIT, as well as their interactions 
with probiotic bacteria. The knowledge of this microbiota that is underway has increased our 
understanding of the beneficial effects of probiotics on the human and animal health. 
Prior to birth, humans develop in a sterile environment, the womb. However, the rupture of 
the membranes at delivery exposes the neonate to a wide variety of microorganisms, 
especially those that colonize the GIT, forming its microbiota. Over the course of human 
development, this microbiota undergoes variations according to the stages of life and 
related to the habits and habitats to which the individual is exposed (Isolauri et al., 2004, 
Tiihonen et al., 2010). 
The most dramatic changes in the composition of the intestinal microbiota occur during 
childhood. During the first days of life, the microorganism population is unstable and tends 
to stabilize with breastfeeding or the intake of breast milk substitutes. The greatest change in 
this composition, however, occurs through weaning and the introduction of solid foods 
(Favier, et al., 2002). Throughout adulthood, the intestinal microorganisms are relatively 
stable; however, this stability is reduced in the elderly (Tiihonen et al., 2010). These changes 
can be attributed to dietary restrictions, changes in eating habits and the increased incidence 
of diseases and concomitant medication use, all of which are found with increasing age 
(Gill, et al., 2001, Tiihonen et al., 2010).  
Early studies focused on the changes in the human intestinal microbiota, reporting the 
reduction of anaerobes and bifidobacteria and an increase of enterobacteria in the elderly 
(Mitsuoka, 1990). However, recent studies suggest a lower stability and increased diversity 
of the intestinal microbiota with advancing age (Hopkins and Macfarlane, 2002; Maukonen, 
et al., 2008, Tiihonen et al., 2010).  
The human GIT has a very complex microbial ecosystem that is based on competition and 
symbiosis (Mackie et al., 1999) and consists of at least 400 to 500 different bacterial species, 
approximately 1014 cells (Ott et al., 2004; Zoetendal, et al., 2004; Zoetendal, et al., 2008). This 
population, have the composition which differs both along the gastrointestinal tract as along 
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the lumen to the mucosa (Tiihonen et al., 2010), is affected by several factors; some are 
determined by the interactions between genetic, environmental or disease factors to which 
the individual is exposed, the diet, the secretion of mucus, digestive enzymes and intestinal 
peristalsis. As a result, each individual has a unique characteristic microbiota (Isolauri, et al., 
2004; Ley, et al., 2006).  
The lack of bacteria in the upper GI tract (esophagus, stomach and duodenum) is related to 
the composition of the luminal medium (acid, bile and pancreatic secretions). In addition, 
the propulsive motor activity at the end of the ileum eliminates most of ingested 
microorganisms, preventing the stability of bacterial colonization in the lumen (Guarner and 
Malangelada, 2003). However, the lower portion of the GI tract, comprising the lower 
duodenum and small and large intestines, contains a complex and dynamic microbial 
ecosystem, with a high density of live bacteria reaching concentrations 1011-1012 cells / g of 
luminal contents, which corresponds to 1.5 kg of microorganisms (Moore and Holdeman, 
1974; Whitman et al., 1998; del Piano, 2006). 
In this environment, the permanent organisms that colonize and grow in the place where 
they are found are considered to be autochthonous microbiota, whereas the non-native or 
transients are those that are vehicled by food, water and environmental components passing 
through the region (Ley, et al., 2006)  
The TGI naturally has the function of protecting the body against pathogens and / or toxic 
metabolites. This protection is ensured by a number of factors, including saliva, gastric 
acids, peristalsis, mucus, intestinal proteolysis, intestinal microbiota balance and the 
epithelial membranes with intercellular junctional complexes (Ouwehand et al., 2002). 
The intestinal mucosa forms an interface between the body and luminal environment, with 
the function of allowing the passage of nutrients and simultaneously acting as a barrier 
against microorganisms, toxins and other undesirable substances. The mucus produced by 
the goblet cells exerts this protective function; therefore, the barrier effect is guaranteed by 
the physical, chemical and functional epithelium integrity (Cencič and Langerholc, 2010). 
The balance of the microbiota has been gaining special attention from the scientific 
community for years, and many studies indicate and confirm a close relationship between 
intestinal disbioses and microbial imbalance in addition to intestinal homeostasis and the 
maintenance of the equilibrium of the intestinal microbiota. Some microorganisms, 
particularly the probiotics, have great importance in maintaining this balance.  
Although feces are the most available sample to investigate the intestinal microbiota, it is 
questionable how well the fecal microorganisms represent the intestinal microbiota, as they 
originate from the lumen and the distal colon. Indeed, the composition of intestinal 
microbiota is different in the lumen and the distal colon and throughout the TGI and 
mucosa. Moreover, the TGI has large species diversity and consists of known species and 
those that have not yet been cultured.  
Thus, for more precise information on the gut microbial population, appropriate samples 
should be collected during endoscopies or surgical procedures; however, such invasive 
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procedures are rather unsuitable and rarely used in research. Moreover, the scarcity of 
information on the effects of anesthetics and disinfectants used in these procedures suggests 
the possibility that they may compromise the investigation (Isolauri et al., 2004, Ley, et al., 
2006). Therefore, the approaches of studies on human intestinal microbiota are usually 
based on in vitro or animal models and in the evaluation of the fecal microbiota. 
3. Probiotics and human health 
Evidence derived from clinical and mechanistic studies indicate that the health benefits 
promoted by healthy lifestyle habits and the consumption of a balanced diet rich in 
bioactive ingredients are approaches that are increasingly attractive to the pharmaceuticals 
and food industries in addition to the general population. 
Functional foods are defined as any substance or constituent of a food that, in addition to 
providing basic nutrition, promotes metabolic and / or physiological health benefits 
(Walker, et al., 2006). These foods are broadly grouped into conventional foods, bioactive 
substances and synthesized foods. In general, the term refers to a food that has been 
modified to become functional or that naturally contains bioactive compounds. Functional 
foods are also known as designer foods, medicinal foods, nutraceuticals, therapeutic foods, 
superfoods, foodiceuticals, and medifoods (Shah, 2007). 
Thus, the probiotic microorganisms capable of promoting beneficial effects in a host for the 
production of bioactive compounds or the equilibrium of the intestinal tract are often 
associated with functional foods.  
There is a long history of health claims concerning the beneficial effects of probiotic 
microorganisms in food, particularly lactic acid bacteria and bifidobacteria. Additionally, 
studies involving probiotic microorganisms have distinguished these microbes into different 
categories according to their mode of action, the aims of the administration of the probiotics 
and their mode of administration in addition to claims regarding legal regulations.  
4. Probiotics: History and concepts 
There is a long history of the beneficial effects that some microbes have on human health, 
with the effects of lactic acid bacteria, in particular, being the earliest record. In a Persian 
version of the Old Testament (Genesis 18:8), there is a statement that “Abraham owed his 
longevity to the consumption of sour milk.” In 76 BC, the Roman historian Plinius 
recommended the administration of fermented dairy products for the treatment of 
gastroenteritis (Bottazzi, 1983; Schrezenmeir and de Vrese, 2001). However, studies 
involving these organisms and their clinical effects in animals and humans are 
contemporary and are based on the production of beneficial substances and / or the 
promotion of a balance that favors the microbial host. 
The concept of beneficial microorganisms has been attributed to Lactobacillus bulgaricus 
when, more than a century ago, Elie Metchnikoff (1905) emphasized the importance of 
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lactobacilli in the intestinal microbiota, providing the properties of health maintenance and 
longevity to the host. However, the term “probiotics” was proposed decades later by Lilly 
and Stillwell (1965) in reference to a substance secreted by protozoa in symbiosis. Parker 
(1974) first used the concept of combining the use of organisms or substances, as opposed to 
antibiotics, to contribute to the balance of intestinal microbiota. The term was later 
popularized by Fuller (1989) and defined as a probiotic food supplement based on live 
microorganisms with beneficial effects to the host in balancing the intestinal microbiota. 
The term “probiotic” has been widely used, and according to research data, the general 
concept has experienced subtle changes. Schrezenmeyer and Vrese (2001) defined the term 
as a microorganism preparation or product containing viable microorganisms in sufficient 
numbers to change, through colonization, the host microbiota, thus promoting health 
benefits. Salminen and colleagues (1999) defined probiotics as microbial cell preparations (or 
components thereof), viable or inactive, with favorable effects on the health and welfare of 
the host. Clearly, the benefits must be evaluated in terms of the mechanisms and properly 
established and documented selection criteria. 
Some authors also extend the action of probiotics to inactive cells and argue that both living 
and dead cells in probiotic products can produce beneficial biological responses (Havenaar 
et al., 1992; Adams, 2010). This approach will open new perspectives for research, for 
example, about the amount of cells needed and the proportion viable / non-viable cells 
required to obtain the desired effect. Furthermore, the use of inactivated probiotics has 
attractive advantages, such as consumption safety and the possibility of products with long 
shelf lives (Adams, 2010). 
The WHO and FAO (World Health Organization and Food and Agriculture Organization of 
the United Nations) maintain the general concept that defines probiotics as live 
microorganisms that, when consumed in adequate amounts, confer benefits to the host 
(FAO / WHO, 2001). In Brazil, according to the currently enforced food legislation, the 
National Sanitary Surveillance Agency (ANVISA) has set forth that, to produce the claimed 
benefits of a probiotic food, the product should contain a minimum number of viable 
probiotic cells between 108 and 109 Colony-former unit (CFU) per day (BRAZIL, 2008).  
However, the scientific community agrees that the effects of probiotic microorganisms can 
vary depending on the species, the quantity ingested and the physiologic characteristics of 
the host. Furthermore, the current evidence suggests that the probiotic effects are species 
and even strain specific (FAO/WHO 2002, Isolauri et al., 2004, Tiihonem et al., 2010).  
Although the Lactobacillus and Bifidobacterium have been predominantly used as commercial 
probiotic; the market is not exclusive to these genera. In fact, is growing the number of 
probiotic foods available to the consumer. Based in scientific studies, the regulatory agencies 
worldwide have characterized a broader number of microorganisms as probiotics. Because 
the technologic and functional characteristics, these strains have been used in food and 
pharmaceutical industry (Table 1).  
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Species Strains
Bacillus lactis DR10™
Bifidobacterium adolescentis ATCC 15703, 94-BIM
B. animalis and subspecies lactis BB-12™
B. breve Yakult™, BB-03
B. bifidus BB-11™
B. essencis Danone™
B. infantis Shirota™, Immunitas™, 744, 
B. lactis Bb-02, Lafti™, DSM-B94, DR10™
B. laterosporus CRL431
B. longum BB536, SBT2928, UCC 35624
Lactobacillus acidophilus LA-1™, La-5™, NCFM, DDS-1, SBT-2062, La-14™ 
L. casei Shirota™, LC™, DN1114001™, Immunitas™ 
L. casei shirota Yakult™
L. casei ssp. defensis Danone™ 
L. lactis L1A, 
L. fermentum RC-14
L. helveticus B02
L. johnsonii La1™
L. paracasei CRL 431™
L. plantarum 299 Probi™, LP115™, Lp01 
L. rhamnosus GG, GR-1, LB21, 271Probi™
L. reuteri SD2112
L. salivarius Ls-33
Sacharomyces cereviseae NCYC Sc 47
S. boulardii 17™
Table 1. Some microorganisms used as probiotic cultures in commercial products. 
The characterization of the probiotic species or strain is supported by the screening of 
resistance to the adverse conditions in the TGI. To survive passage through the TGI, microbes 
must exhibit a resistance to a low pH, bile and pancreatic enzymes. Moreover, it is desirable 
that these bacteria display adhesion to the intestinal mucosa and pathogen exclusion abilities 
and have positive effects on the immune system of the host; evidently, these bacteria should be 
non-pathogenic and have a GRAS (Generally Recognized as Safe) status. These effects are 
evaluated by intensive in vitro and in vivo approaches. The intestinal homeostasis relies upon 
the equilibrium between substance absorption, secretion and the barrier capacity of the 
digestive epithelium, and probiotic microorganisms are highly related to homeostasis. 
The scientific literature reports sufficient data to demonstrate that the benefits attributed to 
probiotics are inherent to their population increase in a given environment, concomitant 
with a decrease in potentially pathogenic bacteria (Jankovic et al., 2010). In addition, it had 
been demonstrated for more than 20 years that the intestinal microbiota of healthy 
individuals is altered with the ingestion of probiotics in favor of lactobacilli and 
bifidobacteria species. Although such alterations and the beneficial effects in healthy 
populations remains a complex issue (Saxelin, et al., 1993; de Vrese, et al., 2006), there is a 
 
Probiotics: The Effects on Human Health and Current Prospects 373 
consensus on the association of disbioses with chronic inflammatory diseases (Manichanh, 
et al., 2006), obesity (Ley et al, 2006) and allergies (Penders et al., 2006). 
There has been a substantial increase in the number of articles published in scientific 
journals and the lay press, focusing on the popularity of probiotic foods and their effects. 
Thus, the FAO and WHO (2001) established scientific committees, whose discussions have 
produced a document with guidelines designed to regulate the characterization of 
potentially probiotic microorganisms, ensure the security of the host, assess at the 
technological and commercial aspects of probiotics in food and evaluate the clinical proof of 
the expected effects on individuals (FAO / WHO, 2002). 
Understanding the complex microbial system of the TGI will help to characterize the 
intestinal microbial community and recognize the mechanisms by which probiotics exert 
their effect on the health of humans and animals. Although the traditional culture-based and 
phenotypic techniques used to study this complex ecosystem are unfeasible, the current 
molecular approaches have increased our knowledge of the structure, diversity, interactions 
and mechanisms that influence the dynamics of the TGI microbial community. 
5. Molecular approaches in the study of probiotic microorganisms  
Studies of the gut microbiota that use traditional techniques for microbial cultivation are 
supported by phenotypic analysis based on morphological and biochemical characterization. 
These techniques are laborious, time consuming, subject to misinterpretation and identify only 
approximately 40% of the microbiota (Carey et al., 2007). The reasons for the deficiencies in 
microorganism cultivation by traditional methods include ignorance of the nutritional profile 
of the microorganism, culture medium selectivity, the stress imposed by cultivation 
procedures, the need to restrict the environmental conditions and difficulties in simulating the 
host interactions with microorganisms (Zoetendal, et al., 2004).  
Research involving nucleic acid analysis indicated that the majority of the bacteria in a variety 
of ecosystems are different from those related on the cultivation methods. This idea led to the 
development and application of methods that are independent of the culture medium to study 
complex microbial ecosystems (Zoetendal, et al., 2004; Zoetendal, et al., 2008). 
The polymerase chain reaction (PCR), developed by Kary Mullis in the 1980's, enabled the in 
vitro production of multiple copies of specific DNA sequences, without cloning (Alberts, et al. 
1994). Variations of this technique have targeted the needs and advancement of biotechnology.  
In addition, LAB and bifidobacteria have received much attention, especially since the creation 
of the consortium for sequencing the genome of these microorganisms (Lactic Acid Bacteria 
Genome Consortium - LABGC) in the U.S., which culminated in the genomic sequencing of 
industrial strains and many other relevant sequences that are ongoing. Currently, fourteen 
strains of Lactobacillus and ten strains of Bifidobacterium have been sequenced by the 
consortium (http://www.jgi.doe.gov/genome-projects/) or by private initiatives, such as B. 
longum NCC2705 in 2002, the first bifidobacteria to have its genome sequenced, and L. 
plantarum WCSF1 in 2003, the first Lactobacillus sequenced (O'Flaherty et al., 2009).  
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Molecular approaches to evaluate phylogeny and genetic and chemotaxonomic identification 
of the related species have been used successfully in the recent decades in studies. 
Additionally, the use of bioinformatics tools, along with access to available databases in the 
GenBank / NCBI (National Center for Biotechnology Information) has boosted research, 
aiming at the development of strategies for identifying target species (Costa, et al., 2011).  
The significant increase in the knowledge of the structure, diversity and factors that 
influence the GIT microbial community dynamics and the mechanisms by which probiotics 
may influence intestinal homeostasis are due to ready access to their genomic data. 
Furthermore, the variety of in vivo immunoassays aimed at elucidating the physiological 
effects of probiotic therapies and the molecular approaches based on PCR, ribotyping and 
hybridization with probes have also contributed to the body of knowledge (Vaugh, et al., 
2005; Walker, et al., 2006; Carey, et al., 2007). 
Molecular markers are successfully employed in this environment favorable to the 
identification of probiotic microorganisms, and various molecular techniques have become 
powerful tools. Indeed, there are a large number of techniques that are useful for the 
identification of Lactobacillus in different environments (Moreira et al., 2005, , Costa, et al, 
2011), the detection of pathogenicity genes in foods (Bottero, et al., 2004), the identification 
and quantification of bifidobacteria via real-time PCR (Masco, et al, 2007). In addition, 
proteomic approaches evaluates the expression of genes of interest or changes in the host 
related to the effects of the microorganisms (Yuan, et al. 2008; O'Flaherty, et al., 2010). 
The use these of technologies associated with suitable choice of the molecular marker is very 
important to differentiate closely species. The recA gene has provided a high discriminatory 
ability for the differentiation of the LAB species (Figure 1). 
Furthermore, studies employing the sequence analysis of genes for microorganism 
genotyping, such as ribosomal small subunit rRNA (SSU rRNA), allow the expansion of the 
knowledge about the diversity of the gut microbiota. Only a decade after the introduction of 
genotyping, the number of species molecularly detected in the TGI has greatly exceeded the 
number of species accessible using cultivation-dependent methods (Zoetendal, et al., 2008). 
One of the most increasingly used techniques is real-time PCR or quantitative PCR (qPCR), 
which identifies and quantifies organisms of interest. This technique, coupled with the use 
of specific primers, has proven to be an accurate method that is suitable for the identification 
and quantification of microorganisms (Matsuki, et al., 2004). Moreover, this tool provides 
new perspectives in the studies of the diversity, abundance and dynamics of the intestinal 
ecosystem (Walker, et al, 2006; Masco, et al., 2007, Zoetendal, et al., 2008). Thus, the qPCR 
has attracted attention for being a reliable method that is highly sensitive for the detection 
and quantification of many organisms in different environments. 
The technique is based on the traditional technology of PCR in combination with 
compounds that fluoresce at certain wavelengths, making it possible to monitor the amount 
of PCR products generated in each reaction cycle (Wittwer et al., 1997; Vitali, et al., 2003).  
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Figure 1. The phylogenetic tree consensus from the recA gene sequence comparisons, demonstrating the 
relationship of closely related species of the BAL, Bifidobacterium and enteric bacteria. The tree was 
constructed with the Neighbor-Joining method and the Clustal W algorithm. Genetic distances were 
computed by using Nei’s coefficient. Bootstrap values based on 1000 replicates are provided at branch 
nodes. The B. thuringiensis sequence was included as an out-group sequence.  
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The methods used for qPCR are based on the measurement of the fluorescence emitted as a 
function of the value of the cycle threshold (CT) or Crossing Point (CP), which is posteriorly 
related to mathematical expressions for absolute or relative quantification (Livak and 
Schmittgen, 2001; Pfaffl, 2001). The CT method is directly related to the quantity of the 
amplification product in the PCR reaction.  
The normalization of the target gene using an endogenous standard is recommended (Pfaffl, 
2001). The addition of a gene normalizer to the reaction is highly recommended and is 
intended to correct any concentration differences or defects in DNA extraction. 
Normalization ensures that fluctuations in the signal strength due to impurities or amounts 
of target DNA below the detection limit are taken into account during the analysis. 
However, the uniformity of the normalizer gene during the entire process or the stability of 
the expression during the experimental treatment must be confirmed (Kubista, et al., 2006; 
Marcelino, 2009; Hofstätter, et al., 2010; Dang and Sun 2011). 
In the development of these methodologies, some alternatives have emerged to further 
refine the technique. Thus, the application of qPCR to quantify only viable cells (vqPCR) has 
eliminated one of the common criticisms in the quantification of probiotic microorganisms 
because qPCR does not distinguish between viable and non-viable cells. 
The approach of vqPCR is based on the differentiation between viable cells and non-viable 
cells based on the membrane integrity. Theoretically, the selective dye used can only 
penetrate the permeable membranes of dead cells and intercalate extracellular DNA. The 
dye makes the DNA unavailable for amplification due to the presence of an azide group, 
present in such substances as ethidium monoazide (EMA) or propidium monoazide (PMA), 
which allows cross-links between the dye and DNA after the exposure to high-intensity 
visible light. The photolysis of these substances (EMA and PMA) converts the azide group 
into a highly reactive nitrene radicals, which can react with any organic molecule in its 
vicinity, including DNA, which then cannot be amplified by PCR (Varma, et al., 2007; 
Fitipaldi, et al., 2010). 
Unquestionably, the use of genetic tools has accelerated the knowledge and understanding of 
the complexities found in the intestinal microbiota and their interactions. It is now possible to 
gain a better comprehension of the role of these organisms, including the accurate analysis of 
the functionality of probiotics and to obtain strains lacking one or more proteins (O'Flaherty 
and Klaenhammer, 2010). Furthermore, it is obvious that an understanding of the interactions 
through the cross-talk between the intestinal microbiota and its host would expand the 
knowledge of the relationship between microbiota and their effects on health.  
There is an increasing tendency of probiotic studies to focus on metagenomics (Ventura, et 
al, 2009), which is, which is defined as the study of the collection of genomes of an 
ecosystem and can be used to study the phylogenetic, physical and functional properties of 
microbial communities. From the point of view of functional genomics, the application of 
these technologies provides a wealth of information and fosters research aiming at a better 
understanding of probiotic microorganisms and their effects. 
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6. Market prospects 
The interest in functional foods is directly related to the growing appreciation of the quality 
of life and disease prevention because these foods affect specific functions or systems in the 
human body and are intended to complement basic nutrition (Shah, 2007). The food 
industry has developed a variety of new products containing active ingredients that 
promote consumer health. 
The global market for functional foods generated US$ 32.07 billion in 2000 and US$ 68.39 
billion in 2005; in 2010, the total surpassed US$ 150 billion and continues to expand (Granato 
et al., 2010). Latin America is considered an emerging market, and despite the general lack 
of nutritional knowledge by the population, Brazil and Mexico are potential trade markets 
for probiotics (Granato et al., 2010). The probiotic market in Latin America grew 32% per 
year between 2005 and 2007 (Crowley, 2008), and the annual sales growth rate of probiotic 
drinks and yogurts was 5% between 2006 and 2011 (Özer and Kirmaci, 2010). 
Among the functional foods, dairy products with functional claims accounted for almost 
43% of the world market between 2005 and 2010 (Özer and Kirmaci, 2010). In this scenario, 
the use of probiotic microorganisms in foods and pharmaceuticals had such an increase in 
the world market, that the sales reached $ 15 billion in 2007, amounted to $21.6 billion in 
2010 with the prospect of more than $ 31.1 billion by 2015 (Agheyisi, 2011).  
Following the same trend, the sales of foods with functional claims reached $ 500,000 in 
2007, representing 1% of the total spending on food in Brazil (Cruz, et al, 2007; Granato, et 
al., 2010). According to Euromonitor International Consulting data released in 2010, the 
market for products for intestinal microbiota balance had a 60% growth in Brazil in five 
years, from R $ 57 million in 2004 to $ 92 million in 2009 (Revista Fator, 2011). 
Over the last two decades, a substantial number of research studies have supported the idea 
that health can be affected by the daily consumption of probiotic foods (Heyman and 
Menárd, 2002), with clinical evidence demonstrating the actual effect of these organisms to 
the host. These data provide an understanding of the mechanisms by which probiotic 
microorganisms survive the passage through the GI tract to interact with the resident 
microbiota and affect physiological functions in the host. In addition, there is much 
investigation into both the classification of probiotic strains and the production technologies 
and regulation of the products. 
To assess the impact of scientific research in the dissemination and consolidation of the 
benefits of probiotics in the diet, a search was conducted using three major scientific 
databases (Isi Web of Knowledge, Pub Med and Scopus). The search was restricted to two 
periods, and the key word “probiotic” in the title of the publication was used as a selection 
parameter. On average, there were 410 publications from 1991 to 2001, whereas 2406 records 
were found in the 2002 to 2011 period. According to the database Isi Web of Knowledge, in a 
period of ten years (2001 to 2011), 2686 publications were available in the database, 
documenting 791 patents, and 100 records are related to reviews; all of the other 
publications are related to primary literature.  
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Clearly, in a market in which product development should meet the needs of the consumer, it 
is important that scientific research does not neglect the technology and logistical aspects or 
the regulations of each country. The market will continue to grow as consumers maintain an 
interest in the products offered; however, the credibility of the product is based on its effects, 
which are often supported by scientific studies and the "know-how" from the manufacturer. 
The majority of probiotic products on the market includes Lactobacillus and/or 
Bifidobacterium species but also yeasts; Bacillus and Enterococcus are common in these 
products. (Shah, 2007; Gaggìa, et al.; 2010). Some probiotics marketed in food and 
pharmaceutical industries worldwide, the microorganisms involved, category of product, 
manufacturer and country from origin are listed in Table 2. 
Country Category 
Commercial 
brand 
Manufacturer Probiotic 
Australia Ingredient Probiomics Bioxyne L. fermentum VRI003 (PCC)  
Brazil 
Capsules Floratil Merck S. boulardii
Sachet Fiber Mais Flora Nestlé Lactobacillus reuteri 
 
Activia Danone B. animalis DN173010 
Actimel Danone L. casei defensis 
Batavito Batavo L. casei
Chamyto Nestlé L. jonhsonii/ L. helveticus 
Danito Danone L. casei
Leite fermentado Paulista L. casei
Leite fermentado Parmalat 
L. acidophilus/L. casei/ B. 
animalis subsp. lactis 
Sofyl Yakult L casei shirota
Vigor club Vigor L. acidophillus/L. casei 
Yakult Yakult L. casei shirota
Traditional 
yogurt or 
Drinking yogurt 
Activia Danone B. animalis DN173010 
Biofibras Batavo B. animalis/ L. acidophilus 
Lective Vigor B. animalis subsp. lactis 
Nesvita Nestlé B. animalis subsp. lactis 
Cheese 
Equilibra Danubio B. animalis
 SanBIOS 
Coop. Santa 
Clara
B. lactis 
Canadian/
USA 
Capsules, 
Fermented Milk, 
Fermented soy 
and Fermented 
rice 
Bio-K+ CL1285 
Bio-K+ 
International 
L. acidophilus CL1285 & L. 
casei LBC80R 
France 
Fermented milk DanActive Danon 
L. casei DN-114 001 ("L. 
casei Immunitas") 
Ingredient Lacteol 
Laboratory 
Houdan 
L. acidophilus LB 
 
Probiotics: The Effects on Human Health and Current Prospects 379 
Country Category 
Commercial 
brand 
Manufacturer Probiotic 
Japan 
Fermented milk Yakult Yakult  
L. casei Shirota 
B. breve strain Yakult  
Ingredient  
Morinaga
Milk Industry 
Co Ltd
B. longum BB536 
Sweden 
Juice 
GoodBelly
ProbiMage 
Probi L. plantarum 299v 
Juice, Cultured 
Milk 
ProViva Probi L. plantarum 299v 
Juice 
Bravo Friscus/ 
ProbiFrisk 
Probi 
L. plantarum HEAL 9 & L. 
paracasei 8700 
Probiotic 
chewable tablets 
or drops
Protectis Biogaia L. reuteri ATCC 55730 
Switzerland Fermented milk LC1 Nestlé  
L. johnsonii Lj-1 same as 
NCC533 
UK  
Floralfit (Blend 
strains) 
 
L. acidophilus La14, L. casei 
Lc11, L. salivarius Ls-33, L. 
plantarum Lp115, L. 
rhamnosus, Lr-32, B. lactis 
Bl-04 & B. longum Bl05. 
USA 
Capsules Align 
Procter & 
Gamble
Bifidobacterium infantis 
35624
Supplement GanedenBC 
Ganeden 
Biotech
Bacillus coagulans GBI-30, 
6086
Capsules 
Florajen products 
(blend or only 
strain)
American 
Lifeline, Inc 
L. acidophilus, 
Bifidobacterium lactis & 
B. longum 
Yogurt Activia Dannon B. animalis DN173 010 
Dairy products 
Frozen Kefir, 
Milk cultured 
kefir, Traditional 
kefir 
Lifeway 
Foods Inc. 
L. acidophilus, L. casei, L. 
lactis, L. rhamnosus, L. 
reuteri, B. breve, B. lactis, L. 
plantarum, B. longum, 
Leuconostoc cremoris, 
Sacharomyces florentinus  & 
Streptococcus diacetylactis. 
USA/ 
Finland 
Supplements or 
Chewable for 
kids 
Culturelle, 
Dannon 
Danimals
Valio and  
Dannon  
L. rhamnosus GG ("LGG")  
Table 2. Foods and pharmaceuticals probiotics products, marketed worldwide, manufacturer and 
microorganism in use.  
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The probiotic market is constantly changing. Within this context, many innovations that 
direct studies and the functional microorganism market are being applied, and there are 
prospects of many other approaches because this branch of science is challenging. 
What factors are predominant in the probiotics development? From the standpoint of 
marketing, the factors are a fully expanding open field, and the numbers reflect this 
scenario. From a scientific standpoint, many studies are aimed at the selection of strains 
with desirable and efficient characteristics, invoking the research of new effects and the 
elucidation of the mechanisms of action. The application of techniques for the functional 
genomics of probiotic bacteria certainly will accelerate the development of such products 
(de Vos, et al., 2004). 
Furthermore, advances in the “genomic era” will increasingly be used to answer questions 
related to interactions between organisms. Molecular biology and its tools, the access to 
molecular databases, and the speed with which information is disclosed are essential for 
accurate identification of the benefits attributed to probiotics. 
Most of the probiotic bacteria currently marketed were selected on basis on their technological 
properties, but not for their ability to confer health benefits. However, is evident that the use 
and development of novel technologies aiming products that meet the nutritional and 
physiological requirements desired by the target population is a priority among research and 
Industries. Additionally, the “feedback” among science, industry and the market is extremely 
important, and is desired that there is dynamism between these sectors. 
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